BRISTOL-MYERS SQUIBB COMPANY Contractual Obligation
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Contractual Obligation of $6.40 billion as of 2021-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:ContractualObligation · last filed 2026-07-30
- 2021-06-30: Contractual Obligation $6.40B.
| Period end | Contractual Obligation |
|---|---|
| 2021-06-30 | $6.40B 10-Q · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |